Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | HCK | P08631 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29083255 | 0.86 | MEN1 (0.45) | RAB9ANPC1POLBSMN1; SMN2KDR | |
| SCHEMBL2561277 | 0.86 | SMN1; SMN2 (0.53) | RAB9ANPC1POLBSMN1; SMN2KDR | |
| SCHEMBL13504162 | 0.85 | LMNA (0.58) | RAB9ANPC1POLBSMN1; SMN2MAPK14 | |
| SCHEMBL14687925 | 0.85 | RAB9A (0.52) | RAB9ANPC1POLBSMN1; SMN2HCK | |
| SCHEMBL13504214 | 0.84 | NPC1 (0.53) | RAB9ANPC1POLBSMN1; SMN2GSK3A | |
| SCHEMBL29788823 | 0.84 | GCK (0.56) | RAB9ANPC1POLBSMN1; SMN2KDR | |
| SCHEMBL2551479 | 0.84 | GCK (0.56) | RAB9ANPC1POLBSMN1; SMN2KDR | |
| SCHEMBL13504228 | 0.84 | MEN1 (0.54) | RAB9ANPC1POLBSMN1; SMN2KDR | |
| SCHEMBL2561684 | 0.84 | SMN1; SMN2 (0.48) | RAB9ANPC1POLBSMN1; SMN2GSK3A | |
| SCHEMBL29083248 | 0.83 | POLB (0.42) | RAB9ANPC1POLBSMN1; SMN2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | RAB9A 2492/4885NPC1 2933/4885POLB 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.